ent to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visitwww.samsungbioepis.comand follow us onLinkedInandX.






Contacts


Media Contact
Yoon Kim,yoon1.kim@samsung.com
Anna Nayun Kim,nayun86.kim@samsung.com







=*=*=*=*=*=
当前为第3/3页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页